"Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. [Wikipedia]"@en . "Humans and other mammals"@en . "Bexaroten"@en . "Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies."@en . . . . . "# Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S: The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007 Sep;157(3):433-40. Epub 2007 Jun 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17553039 # Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E: A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007 Mar 15;13(6):1794-800. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17363535 # Smit JW, Stokkel MP, Pereira AM, Romijn JA, Visser TJ: Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab. 2007 Jul;92(7):2496-9. Epub 2007 Apr 17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17440015 # Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11702369 # Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16495926 # Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15056048"@en . . "Bexaroteno"@en . "Bexarotene"@en . . "Bexarotene"@en . "approved"@en . . "Targrexin"@en . "4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid"@en . . . "P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid"@en . . . . . . . . . . . "Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR_\u03B1, RXR_\u03B2, RXR_\u03B3. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL."@en . "7 hours"@en . . . . . . . . . . . . . . . . ">99%"@en . . . . . . "Urinary elimination of bexarotene and its known metabolites is a minor excretory pathway (<1% of administered dose)."@en . . "Targretyn"@en . . . "153559-49-0"@en . . . . "Bexarotenum"@en . . "4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid"@en . . . . . "investigational"@en . "\"DrugSyn.org\":http://www.drugsyn.org/Bexarotene.htm"@en . . "Bexarot\u00E8ne"@en . . "p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid"@en . .